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Abstract
In this retrospective observational study covering 1998 to 2008,
32 patients (mean age: 7.50 years) were identiﬁed that had 35
episodes of candidaemia (0.47 cases/1000 hospital discharges).
Cancer/allogeneic haematopoietic stem cell transplantation (43%)
and congenital malformations/syndromes (21%) were the predom-
inant underlying conditions. Central venous catheterization (90%),
a history of antibacterial therapy (69%) and previous bacteraemia
(54%) were frequent comorbidities. Candida albicans (46%) was
most common, followed by Candida parapsilosis (17%) and Candida
glabrata (14%). Resistance was infrequent and limited to non-
albicans Candida spp. The 30-day and 100-day mortality rates were
11.4%.
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Bloodstream infections by Candida spp. are an important
cause of infectious morbidity and mortality in hospitalized
patients [1]. Although there are several important investiga-
tions on the epidemiology of paediatric and neonatal candida-
emia from the USA [2–9], comparable studies from Europe
are restricted to Mediterranean countries [10–12]. We
therefore analysed the incidence, demographic features and
outcome of bloodstream infections due to Candida spp.
among patients admitted to a German Paediatric University
Hospital.
The study was a single-centre, retrospective observational
cohort analysis covering the period from August 1998 to July
2008. The University Children’s Hospital is an academic ter-
tiary-care hospital and serves a population of c. 2.6 million
residents. It consists of four departments (Paediatrics, Cardi-
ology, Haematology/Oncology, Surgery) with c. 140 beds and
7500 hospital admissions/year. It has a 17-bed interdisciplin-
ary intensive-care unit (ICU) with c. 650 admissions/year, and
a haematopoietic stem cell transplantation (HSCT) pro-
gramme with c. 20 allogeneic transplants/year. Patients eligi-
ble for inclusion had to have an episode of candidaemia,
deﬁned as the isolation of a Candida spp. from one or more
blood cultures. Cases were identiﬁed through review of the
Medical Microbiology records, and microbiological and clini-
cal data were captured by a pseudonymized standardized
case report form. Study design and data handling were
reviewed and approved by the local ethics committee. Blood
cultures were performed using BACTEC Peds Plus/F culture
vials and the BACTEC 9240 system (Becton Dickinson, Para-
mus, NJ, USA). Yeast pathogens were sub-cultured on Sab-
ouraud dextrose agar, processed for identiﬁcation by
micromorphology, fermentation and the API C32 identiﬁca-
tion system (BioMe´rieux, St Louis, France), and frozen at –70C.
For susceptibility testing, isolates were freshly sub-cultured and
analysed as batch using a broth microdilution method as
outlined in Table 2 [13–15].
During the 10-year period, 35 episodes of Candida blood-
stream infections in 32 paediatric patients were identiﬁed;
three patients (9%) had two separate episodes of candida-
emia. The pooled average annual incidence was 0.47 cases/
1000 hospital discharges (95% CI, 0.26–0.57) and 0.06 cases/
1000 inpatient-days (95% CI, 0.035–0.073) without trend
over time. The incidence was higher in oncology/HSCT
patients (1.25; 95% CI, 0.74–1.57) compared with ICU
patients (0.59; 95% CI, 0.02–1.09) and cardiology patients
(0.51; 95% CI, –0.07 to 0.95), patients admitted to other
paediatric wards (0.28; 95% CI, 0.00–0.52) and to paediatric
surgery (0.18/1000 discharges; 95% CI, –0.08 to 0.42),
respectively. Candidaemia was infrequent in neonates with
three cases per 3977 hospital discharges (0.75 cases per
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1000 hospital discharges (95% CI, –0.11 to 1.65); 1.08 in
£36th week of gestation versus 0.46 in >36th week of
gestation; 5.9 in <1000 g (n = 1/269); 1.72 in <1500 g (n = 1/
579); 1.3 in <2500 g (n = 2/1588); and 0.41 in ‡2500 g
(n = 1/2386 cases) birthweight, respectively).
The mean duration of hospitalization before onset of can-
didaemia (18.6 days; range, 0–90) was prolonged, and seven
episodes (21.2%) occurred while children were receiving
prophylactic or empiric antifungal therapy (Table 1).
Malignancy including allogeneic HSCT (43.8%) and congenital
malformations/syndromes (21.9%) were the most common
underlying diseases; candidaemia in the context of sequelae
of premature birth was infrequent (3.1%). The most frequent
clinical characteristics associated with the occurrence of
candidaemia were the use of broad-spectrum antibiotics at
presentation (93.9%) or within the previous 2 weeks
(69.7%), the presence of a central venous catheter (90.9%),
and previous bacterial bloodstream infections (54.5%).
Candida albicans was the most common species, accounting
for 45.7%, followed by C. parapsilosis (17.1%) and C. glabrata
(14.3%) (Table 2). There was no trend over time regarding
the relative distributions of C. albicans and non-albicans
Candida species. Non-albicans Candida species dominated in
oncology/HSCT patients (60%; 9/15) and General Paediatric
patients (64%; 7/11), whereas C. albicans was the predomi-
nant isolate in the remainder (60%; 6/9). None of the 32
isolates tested was resistant to all ﬁrst-line antifungal agents,
and resistance was virtually restricted to non-albicans
Candida species. Antifungal therapy was initiated after a mean
of 1.18 days (range, 0–5) following the acquisition of the ﬁrst
diagnostic blood culture. Antifungal monotherapy was admin-
istered in 23 episodes (ﬂuconazole, seven episodes; liposomal
amphotericin B, six episodes; caspofungin, three episodes;
more than one agent sequentially, seven episodes) and com-
bination therapy in ten episodes (30.3%). The mean duration
of all antifungal therapy per episode was 25.5 days (range,
3–70). Most central venous catheters (80%, 24/30) were
removed; the median time between the ﬁrst diagnostic blood
culture and the catheter removal was 5.66 days (range,
0–20).
Severe sepsis or septic shock occurred in nine episodes
(27.3%), and metastatic dissemination in ﬁve of the evaluable
episodes (15.2%). Overall, four children (11.4%) died within
30 days of the ﬁrst diagnostic blood culture; the 100-day
mortality rate was the same. Three of the patients with a
fatal course had a malignancy as underlying disease,
accounting for a mortality rate in oncology/HSCT patients of
21.4% (not signiﬁcant versus no malignancy/HSCT; chi-
squared test). All four children who died had complicated
candidaemia (severe sepsis/septic shock; dissemination) in
comparison to six children (20.7%) among the survivors
(p <0.005). The Candida species isolated in the four children
who died included C. albicans (two children) and C. lusitaniae
(two children).
This is the ﬁrst study from Germany describing the cur-
rent clinical and microbiological epidemiology of Candida
bloodstream infections among an unselected population of
hospitalized paediatric patients. With the exception of pre-
mature birth and low birthweight, underlying conditions and
comorbidities were not different from those of other general
paediatric series [4,5,7,8,16–18]. The pooled annual rate of
candidaemia was 0.47 cases/1000 hospital discharges with
higher rates in oncology/HSCT patients (1.25/1000), neo-
nates (0.75/1000), ICU patients (0.59/1000) and cardiology
patients (0.51/1000). These incidence rates are within those
reported in adults [1] but are ﬁve-fold to more than ten-fold
lower than those reported for paediatric patients from the
TABLE 1. Demographic data and clinical characteristics of
patients with candidaemia
Variable
Mean (range)
or n/x (%)
Age (years) 7.50 (0–19)
Gender (male) 16 (50%)
Days of prior hospitalization 18.6 (0–90)
Prior antifungal therapy 7/33 (21.2)
Underlying disease
Malignancy including allogeneic HSCT 14/32 (43.8)
Haematological malignancies 6
Paediatric solid tumours 5
s/p allogeneic HSCT 3a
Congenital malformations/syndromes 7/32 (21.9)
Cardiac malformations ± syndromes 3
Gastrochisis 1
Short bowel syndrome 1a
Complex retardation after premature birth 1a
Complex retardation plus syndrome 1
Metabolic disorders 4/32 (12.5)
Methylmalonic aciduria 3
Glutaric aciduria 1
Surgery, trauma, other acute conditions 4/32 (12.5)
s/p blunt abdominal trauma 1
s/p mastoidectomy 1
s/p appendectomy 1
Haemolytic uraemic syndrome with bowel perforation 1
Solid organ transplantation 2/32 (6.2)
s/p renal transplantation 2
Clinical characteristicsb
Neutropenia at presentation 10/33 (30.3)
Neutropenia in the last 2 weeks 8/33 (24.2)
Steroid use in the last 2 weeks 9/33 (27.3)
Immunosuppressive agents other than steroids 14/33 (42.4)
Mucositis at presentation 5/33 (15.2)
Graft-versus-host disease 2/33 (6.1)
Chemotherapy in the last 2 weeks 14/33 (42.4)
Abdominal surgery in the last 2 weeks 11/33 (33.3)
Total parenteral nutrition 7/33 (21.2)
Azotaemia at presentation 3/33 (9.1)
Dialysis at presentation 2/33 (6.1)
Central venous catheterization 30/33 (90.9)
Broad-spectrum antibiotics at presentation 31/33 (93.9)
Broad-spectrum antibiotics in the last 2 weeks 23/33 (69.7)
Bacterial BSIs in the last 2 weeks 18/33 (54.5)
BSI, bloodstream infection; HSCT, haematopoietic stem cell transplantation; s/p,
status post.
aOne patient had two episodes of candidaemia.
bThirty-three evaluable episodes.
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USA and Mediterranean countries, particularly for neonates
[2,7,8,10,12]. The reasons for these differences are unknown
but may be related to differences in socioeconomic features,
rates of premature births, referral patterns, specialization
and medical practices, as well as to design issues of the dif-
ferent surveys [1].
Similar to other general paediatric series [5,7,8,17,18],
non-albicans Candida species accounted for the majority of
isolates, with C. albicans and C. parapsilosis being the most
frequent aetiological organisms. Resistance to approved ﬁrst-
line agents was limited to non-albicans Candida species, which
is consistent with larger series that included from 120 to
200 Candida isolates [7,17,19]. Apart from a higher rate of
primary combination therapy, the predominant use of
amphotericin B and ﬂuconazole in our study is in line with
other contemporary reports [9,17] and reﬂective of the fact
that newer agents were not approved in children at the time
of the study. The majority of central venous catheters were
removed with rate and timing being similar to those
reported in other series [9,17,18]. Although the mean dura-
tion of all antifungal therapy per episode of 25 days was pro-
longed, this may indicate not only a severely ill patient
population but also uncertainties about treatment endpoints.
The frequency of severe sepsis/septic shock (27.3%) was
similar to reports in a systematic longitudinal study in adults
with Candida bloodstream infections [20] and slightly lower
than in paediatric patients with Candida sepsis mostly
admitted to the ICU [18]. Dissemination to secondary sites
(15.2% in our study) has been reported to occur in 10–20%
of paediatric patients with candidaemia [4,9,21]. Prolonged
fungaemia, use of vasopressors, immunosuppression including
neutropenia, and prematurity have been identiﬁed as
independent risk factors [4,9,21] and may be useful to
identify patients in whom a speciﬁc screening is justiﬁed. The
30-day and 100-day mortality rates were 11.4% and at the
lower end of the range of 10–25% reported in most general
paediatric series [3,9,16,17,22]. Higher mortality rates close
to 50% have been reported, predominantly in studies focus-
ing on ICU patients [8,10,18]. Risk factors for mortality in
paediatric patients with candidaemia include ICU admission
[5,17], mechanical ventilation [16,17], hypotension or the
presence of an arterial catheter [5] and neutropenia [16]. In
contrast to adults [16,23] and similar to other paediatric
reports [9,16], there was no apparent difference in mortality
between C. albicans and non-albicans Candida bloodstream
infections.
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